Redpoint Investment Management’s 10x Genomics TXG Stock Holding History
Bought
Maintained
Sold
Other funds holding TXG
AIM
SIM
GIM
BCM
Redpoint Investment Management's TXG Position: Q2 2022 in Review
Redpoint Investment Management sold out of 10x Genomics (TXG) in Q2 2022, closing a stake of 3,424 shares — an estimated $260K sold.
Redpoint Investment Management first reported a position in TXG in Q1 2022 and held it in 1 quarter. The position peaked at $260K in Q1 2022. 254 funds tracked by Wall St. Rank hold TXG as of Q2 2022.
- Redpoint Investment Management reported no remaining 10x Genomics position as of Q2 2022 after selling out during the quarter.
- Redpoint Investment Management sold 3,424 10x Genomics shares in Q2 2022, an estimated $260K.
- Redpoint Investment Management first reported a position in 10x Genomics in Q1 2022 and held it in 1 quarter.
- Redpoint Investment Management's 10x Genomics position peaked at $260K in Q1 2022.
- 254 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2022.
Based on Redpoint Investment Management's 13F filing for Q2 2022, filed 8 Jul 2022.